Tirofiban

• N-( butylsulfonyl ) -4 - [ 4 - (4 - piperidyl) butyl] - L-tyrosine
• (2S ) -2 - ( Butylsulfonylamino ) -3 - [ 4 - (4 -piperidyl) butoxy ] phenylpropanoic acid
• (S ) -2 - ( Butylsulfonylamino ) -3 - [ 4 - (4 -piperidyl) butoxy ] phenylpropanoic acid
• (S ) -2 - ( Butylsulfonylamino ) -3 - [ 4 - (4 -piperidyl) butoxy ] phenylpropionic acid

B01AC17

White powder

Antiplatelet

223-225 ° C ( tirofiban )

Attention

Template: Infobox chemical / molecular formula search available

Tirofiban is a drug which is used by its effect on platelets ( platelets) as a strong platelet aggregation inhibitor for the treatment of acute coronary syndrome. It is administered as an intravenous infusion.

Operation

Tirofiban, a synthetic inhibitor of glycoprotein IIb / IIIa platelet receptor. This receptor acts as the ultimate bonding site in the process of aggregation of the platelets, which is the first step of each coagulation process. The inhibition by tirofiban is competitive, so reversible.

Indications

Tirofiban is used in unstable angina and non-ST -segment elevation myocardial infarction ( NSTEMI ). It is also an agent that is part of a percutaneous intervention for acute coronary syndromes for use, especially when in the coronary artery blood clots can be displayed.

Adverse effects

Of the continuous infusion of the drug, it is often severe bleeding while slight bleeding is often observed. It can cause headaches, nausea, fever and a drop in the platelet count less than 100,000.

Contraindications and Interactions

Tirofiban may not be used, if the platelet count is less than 100,000, a non-adjustable high blood pressure disease, a clotting disorder or a bleeding risk of the brain disease exists. After major surgery, injury or bleeding six weeks should wait until the drug may be given. Other co-administered substances that interfere in the blood coagulation system, lead to an increased bleeding tendency.

When neuraxial anesthesia procedures ( spinal or epidural ), tirofiban should be discontinued eight hours previously, and given earlier than four hours after the procedure again.

Marketing

The drug was marketed until 2008 by the company Merck Sharp & Dohme under the trade name Aggrastat ®. In January 2008, the rights to the substance of the company Iroko Pharmaceuticals (now Correvio International Sàrl ) were acquired. The list price for 250 ml infusion solution containing 50 micrograms / ml € 261.69 in 2008.